More than $1.5 billion in cash flooded into four IPOs offerings for China-based drug developers this year.
These were just the first. The China biotech IPO opening was — and will continue to be — a big ongoing story.
In April, the Hong Kong Stock Exchange relaxed rules allowing public stock investment in pre-revenue (development-stage) biotech companies. In July, the first such company (Hangzhou-based Ascletis Pharma) took advantage of the situation and went public in Hong Kong. Some predictable Wild West up-and-down stock action ensued. As the initial wave of enthusiasm passes, what are the main forces at work that will shape the market in the year ahead?
Read this exclusive report on Six Things to Watch in China Biotech as you prepare to make the most of China Showcase on Jan. 6, 2019 in San Francisco.
See you there around Union Square.